When a patient arrives with chest pain, abnormal heart readings, and elevated cardiac biomarkers, doctors are often facing a difficult question: is this a heart attack, or is it Takotsubo syndrome, the condition widely known as “broken heart syndrome”?
Researchers are now studying a tool called BioTAK. This score combines blood biomarkers and biological sex and may help distinguish Takotsubo syndrome from acute coronary syndrome before invasive coronary angiography.
In an external validation group of 1,792 patients, the score achieved an AUC of 0.93.
The research focuses on a medical challenge that begins with a simple question but has serious consequences: when two heart conditions look the same, how can doctors tell them apart faster?
A Score Built From Five Biological Signals
BioTAK was designed around the differences doctors can measure between Takotsubo syndrome and acute coronary syndrome.
The researchers analyzed 3,615 patients from the Swiss SPUM ACS and InterTAK registry cohorts. They first developed the score using 1,823 patients, including 1,754 people with acute coronary syndrome and 69 with Takotsubo syndrome.
The team then tested BioTAK in a separate group of 1,792 patients, including 1,715 acute coronary syndrome cases and 77 Takotsubo syndrome cases.
The score combines five factors: biological sex, NT-proBNP, PAM, sLOX-1, and LDL cholesterol. NT-proBNP is a biomarker associated with cardiac wall stress. PAM and sLOX-1 were included because they link to biological processes involved in stress responses, vasoconstriction, endothelial activation, and plaque instability.
The reason researchers focused on this distinction is that Takotsubo syndrome can closely resemble a heart attack in its early stages.
The condition involves temporary left ventricular dysfunction and regional wall motion abnormalities, while acute coronary syndrome often involves a blocked coronary artery.
Doctors may need clinical assessment, imaging, and, in many cases, invasive coronary angiography to determine what is happening.
What the Study Found
BioTAK showed strong separation between the two conditions in the research cohorts, but the results do not represent a finished clinical system.
The score achieved an AUC of 0.97 in the development cohort and 0.93 in the external validation cohort. AUC measures how well a model distinguishes between two groups, with higher values indicating stronger performance.
Using predefined rule-in and rule-out thresholds, researchers reported that nearly 90 percent of patients were assigned to a likely diagnostic category before invasive coronary angiography.
That finding does not mean BioTAK correctly identifies every patient with chest pain, and it does not mean most catheterization procedures could be avoided automatically.
The validation group also showed differences between the two conditions. Among Takotsubo patients, 85.7 percent were female compared with 21.2 percent of acute coronary syndrome patients. The average age was about 70 among Takotsubo patients and 63.5 among acute coronary syndrome patients.
Those numbers reflect the study population and are not a way to diagnose individual patients.
Save this article
Enter your email address and we'll send it straight to your inbox.
Researchers Describe a Possible Addition to Diagnosis
The study authors present BioTAK as a potential support tool for doctors making difficult diagnostic decisions.
Dr. Florian A. Wenzl of the University of Zurich and University of Oxford said: “Our study shows that a simple combination of blood biomarkers and biological sex can identify these patients with remarkable accuracy even before cardiac catheterization.”
Christian Templin of University Medical Center Greifswald and founder of the InterTAK Registry said: “The BioTAK score is not a substitute for cardiac catheterization when it is medically necessary. However, it could help guide diagnostic procedures more effectively and avoid unnecessary invasive tests in selected patients.”
Thomas Lüscher of the National Heart and Lung Institute at Imperial College London said the score translates disease mechanisms related to stress responses, cardiac dysfunction, and plaque stability into a practical diagnostic tool.
Related: 7 Heartbreaking Reasons Young Americans Are Abandoning Love Completely
The Questions That Remain Before Wider Use
The biggest unanswered issue is whether BioTAK can move from research cohorts into everyday medical practice.
The study did not test whether using BioTAK improves survival, reduces complications, shortens emergency department stays, or prevents missed heart attacks.
The reviewed material also does not show that BioTAK is FDA-cleared, included in U.S. guidelines, commercially available in American emergency departments, or validated in a U.S. patient population.
Practical questions remain about testing availability. PAM and sLOX 1 are part of the score, but available reporting does not describe them as standard rapid emergency department tests.
The study included 146 Takotsubo cases across the development and validation groups compared with 3,469 acute coronary syndrome cases. Because Takotsubo syndrome is relatively uncommon among patients evaluated for acute coronary syndrome, the score’s performance may differ in other populations.
Why the Name “Broken Heart Syndrome” Continues to Capture Attention
The nickname made Takotsubo syndrome easy to recognize, but the diagnosis itself depends on careful medical evaluation.
Takotsubo syndrome has been associated with emotional and physical stress, but the research does not show that a specific emotional event directly causes an individual case.
The BioTAK study instead looks at measurable biological patterns linked to the condition, including signals related to cardiac stress and cardiovascular processes.
That tension helps explain why the condition has remained so familiar to the public: the name is simple, while the medicine behind it is not. A phrase people understand emotionally now sits alongside research trying to define the condition with greater precision.
For now, BioTAK remains a promising research tool rather than a replacement for established heart attack evaluation. Its next test will be whether it can provide meaningful value beyond the carefully studied groups that produced the findings.
If a condition can be named after heartbreak but understood through biology, what else might medicine still be learning about the stories our bodies tell?
